RE:RE:RE:What kills credibility I am basing price targets really only on the Anti-aging product discounted .
Once they decide their strategy, and if they go with opening the data to any and all interested parties ,we should get an idea of the level of interest after the typical 6 months multi parties review ie by the end of November 2023 .This also may feed into the share price .
There have been potential estimates on this product line quoted in the past , peak 1 billion USD sales would net 5 to 10 percent to Sirona -depending on negotiating better royalty percentages - 50 to 100 million dollars annually,and I personally see the possibility with the trial data ,I have worked in the health science I should add.
Prior to this week's trial data release ,I stated in recent posts that the best option to look for is a sale of the company due to continuing limited revenue outlook.and ongoing serial dilution to just pay the bills .
This week's make or break data changes everything ,and changes my opinion due to the very high quality of the results ,it basically totally transforms the company's outlook in one news release day.
It is a potent news release for one of the biggest pharma sales market lines out there .
I have a good shareholding ,and yes I will be buying significantly more in the next month or two ,just waiting for some funds to free up from another investment.
I am fine with you or anyone else questioning my perceived optimism ,you are all entitled to your opinions.